Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma.
We report the case of a 59-year-old man with advanced renal cell carcinoma who developed bilateral papilledema while on therapy with sunitinib, a multi-targeted tyrosine kinase inhibitor (TKI). While papilledema has been reported in association with another TKI (imatinib), the association between sunitinib and papilledema has not previously been reported in the literature.
Ballarat Base Hospital, Drummond Street North, Ballarat, VIC 3350, Australia. jackieyoong@hotmail.com
Jaclyn
J
Yoong
Geoffrey
G
Chong
K
K
Hamilton
D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010211:Papilledema / Q000139:chemically induced* / Q000175:diagnosis*; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib
D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib